Compare DexCom, Inc. (DXCM) vs NICE Ltd (NICE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs NICE Ltd — how do they compare? DexCom, Inc. trades at $84.38 (market cap $31.81B), while NICE Ltd trades at $117 (market cap $6.83B). The key difference: DexCom, Inc. is far larger — about 4.7× NICE Ltd's market cap, and DexCom, Inc. is trading nearer its 52-week high, NICE Ltd nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and NICE Ltd for 15 Days on average.
| DXCM | NICE | |
|---|---|---|
Market Cap | $31.81B | $6.83B |
Volume | 2,861,821 | 444,610 |
Sector | Health | Technology |
52-Week High | $92.34 | $137.68 |
52-Week Low | $54.84 | $83.15 |
Typical Hold Time | 62 Days | 15 Days |
Enterprise Value | $31.26B | $6.57B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $84.3, up 1.09% today, with a bearish technical signal but strong fundamentals. Revenue grew to $4.66B in 2025, with net income of $836.3M and a 17.93% margin. The stock has a P/E of 33.32 and P/S of 6.74. Recent news highlights growth in CGM adoption for Type 2 diabetes. Analyst consensus is bullish with an average price target of $95.07, supported by 42 buy ratings.
Outlook remains positive due to earnings beats and market expansion, but risks include competition and reimbursement challenges. The stock offers growth potential, yet investors should monitor execution against high valuations and technical resistance near $85.
NICE (NICE) trades at $116.42, up 0.95% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $124.20. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending. Revenue grew to $2.95 billion in 2025, though net income is projected to decline in 2026. Recent news highlights leadership in AI-driven contact center platforms and positive institutional buying interest.
The outlook for NICE is positive, supported by AI revenue growth and a reasonable valuation, but investors face risks from margin compression and earnings volatility. The stock's proximity to resistance at $118 suggests near-term consolidation may occur before further upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About NICE Ltd
NICE Ltd. is a global leader in both enterprise software and cloud computing, specializing in customer experience and financial crime prevention solutions. The company's platform utilizes advanced analytics, AI, and automation to help organizations enhance customer interactions, ensure compliance, and combat fraud. NICE serves a diverse client base, including contact centers, financial institutions, and government agencies, by optimizing operations and improving service quality.
Read more on NICE →
